Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy

Table 3 Therapeutic outcomes of the experimental participants and controls, n (%)

Characteristic	Experimental group (n = 60)	Control group (n = 50)	P value
CR	0	0	-
PR	16	5	0.023
SD	12	10	1.000
PD	32	35	0.073
ORR	16 (26.70)	5 (10.00)	0.023
DCR	28 (46.70)	15 (30.00)	0.073
PFS (months, mean ± SD)	5.04 ± 1.83	4.69 ± 1.30	0.247
mPFS (months)	5	4	-

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression-free survival; mPFS: Median progression-free survival.